Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   Abstract views HTML views PDF downloads Totals
7,525 Dovepress* 5,742 1,071+ 1,064 6,813
PubMed Central* 0 712 278 712
Totals 5,742 1,783 1,342 7,525
*Since 29 June 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 0 2

View citations on PubMed Central and Google Scholar